One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.
about
Transcellular targeting of fiber- and hexon-modified adenovirus vectors across the brain microvascular endothelial cells in vitroT cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury.Adenoviral vector immunity: its implications and circumvention strategies.The influence of innate and pre-existing immunity on adenovirus therapyNerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS.Single vs. combination immunotherapeutic strategies for glioma.MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsGene transfer into rat brain using adenoviral vectors.Gene delivery with viral vectors for cerebrovascular diseases.Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathologyFiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.CCL2-expressing astrocytes mediate the extravasation of T lymphocytes in the brain. Evidence from patients with glioma and experimental models in vivo.Identification and visualization of CD8+ T cell mediated IFN-γ signaling in target cells during an antiviral immune response in the brain.NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo.Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cellsSafety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialHigh-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.Evading the immune response upon in vivo gene therapy with viral vectors.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaCD20, CD3, and CD40 ligand microclusters segregate three-dimensionally in vivo at B-cell-T-cell immunological synapses after viral immunity in primate brainPreclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma ModelProgress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors.Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivo.Barriers for retinal gene therapy: separating fact from fiction.Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain.Viral vector-mediated gene transfer for CNS disease.Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: prospects and risks.Novel gene therapeutic strategies for the induction of tolerance in cornea transplantation.Genetic therapy for the nervous system.Targeted gene therapy for the treatment of heart failure.Viral vectors for therapy of neurologic diseases.The degenerating substantia nigra as a susceptible region for gene transfer-mediated inflammation.The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies.There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease.Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells.
P2860
Q28484085-A434B55D-2FA6-4AF0-B8A3-4DD9F5DAB8A7Q33361577-64CE55B2-6FD0-411D-A362-BA283B73FDE8Q33565630-9653A081-9F76-4FFF-96A9-21F82E049F96Q33655401-AAB6CB18-967C-461D-AB22-96F086A90614Q33742711-3630D9E0-8182-4585-8AAA-434E99C7B380Q33746041-A7D1E3BB-FCA0-42AC-8980-514AFBC0E2AEQ33832157-7C8AED81-DB0B-43F5-BBB2-9ED7FF1518FAQ33877450-87FA6359-FC35-4241-9C4C-755348C39F00Q33904294-2E86BAE5-8B8A-4088-8335-5E14F6FFE245Q33917592-4C8E9222-1845-4A6E-A5F0-8F259B45E795Q33950709-71C0A965-4E38-4F9F-91A0-E07E5391F995Q34012284-9DE95D9B-84A1-4B68-A418-CE7914DA33C9Q34022048-EB179739-4257-4CDF-BC84-927DFFF9BC28Q34069598-A921FE8B-F80B-4467-AF8B-368D2C51042CQ34102305-31F7ACAC-757D-4252-B912-95C9402D95BCQ34154663-6D60CB73-7FB8-46D0-8A4F-8D663912EF2DQ35185874-448A0FFB-D93C-45AF-862F-61FF25E3B6E5Q35226121-59DC5B78-A11F-43E0-B19A-54B9B0778514Q35876228-5DB82527-8307-48DA-BDFA-DB0AEE73CD80Q36534329-EBA5AF0A-0C88-47F6-A88D-4F59A0E5E337Q36540199-30888DAB-AF60-42E2-858F-C2E2537CB81BQ36644230-760579F5-5D6A-4928-8D58-AFCDF547F712Q36811505-CD0035F7-DEBE-4079-A75E-83E61C9EA04AQ36934011-D0DC6BE9-1F51-47F0-B008-6AB01BD90E60Q37050094-328D9A83-8A71-415F-9457-89157CAAE8F2Q37089746-B5337D20-28C6-4F15-AB3C-64067E8F624FQ37099841-3B3D1059-996A-4D5B-BBA9-9D69C44C004BQ37195446-21C6CDE2-6A4B-4BA8-BA05-A4CC7F0FB085Q37245006-D32EC637-CA7D-49DD-931B-5156CD223594Q37687420-01F47387-FAF2-4A21-A1AE-0DCCE74084E7Q37690581-DFCA7985-1622-4798-9D97-10A7B383D205Q37755334-4583CB91-07AD-43C1-832B-71D30389777FQ37856565-D948999F-FAE2-49D6-BA31-63504C9123DEQ37878086-39D511A4-09F5-494F-9B17-4600125D552BQ38746238-3E11462C-B367-4116-9D39-867434394F52Q39737653-80F3BFC9-FD3C-4697-99D7-E1C18D5CF29EQ41189810-C4706EEE-0F03-4A78-8EB0-E4D63800D5AFQ41785441-7005307C-A5A0-4101-A1A2-7E390EF940F0Q41938249-17AB02B6-AEE0-4921-AFFA-D62EEE703E29Q42592309-823810CE-9E2D-44E2-91D7-8969740569F7
P2860
One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
One-year expression from high- ...... munity: clinical implications.
@ast
One-year expression from high- ...... munity: clinical implications.
@en
type
label
One-year expression from high- ...... munity: clinical implications.
@ast
One-year expression from high- ...... munity: clinical implications.
@en
prefLabel
One-year expression from high- ...... munity: clinical implications.
@ast
One-year expression from high- ...... munity: clinical implications.
@en
P2093
P2860
P50
P356
P1433
P1476
One-year expression from high- ...... mmunity: clinical implications
@en
P2093
Alison J Rapaport
Chunyan Liu
Daniel Larocque
Donna Palmer
Gwendalyn D King
Kurt M Kroeger
Mariana Puntel
Marianela Candolfi
Pedro R Lowenstein
P2860
P304
P356
10.1038/SJ.MT.6300305
P577
2007-09-25T00:00:00Z